Atea Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US04683R1068

SecurityAVIR / Atea Pharmaceuticals, Inc.
InstitutionAlps Advisors Inc
Latest Disclosed Ownership64,862 shares
Latest Disclosed Value $ 348,958
Alps Advisors Inc reports 1.10% increase in ownership of AVIR / Atea Pharmaceuticals, Inc.

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 64,862 shares of Atea Pharmaceuticals, Inc. (US:AVIR) valued at $348,958 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 64,154 shares of Atea Pharmaceuticals, Inc.. This represents a change in shares of 1.10% during the quarter. The current value of the position is $275,664 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 64,862 708 1.10 349 51.97 0.0015
2026-02-12 2025-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 64,154 27,403 74.56 229 116.04 0.0013
2025-11-05 2025-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 36,751 -9,414 -20.39 107 -36.14 0.0006
2025-08-11 2025-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 46,165 46,165 166 0.0010
2025-02-13 2024-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 0 -64,692 -100.00 0 -100.00
2024-11-12 2024-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 64,692 -986 -1.50 217 -0.46 0.0015
2024-08-13 2024-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 65,678 6,311 10.63 217 -9.21 0.0015
2024-05-14 2024-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 59,367 931 1.59 240 34.27 0.0017
2024-02-14 2023-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 58,436 -3,137 -5.09 178 -3.26 0.0014
2023-11-14 2023-09-30 13F ATEA PHARMACEUTICALS COM 04683R106 61,573 271 0.44 185 -19.65 0.0015
2023-08-14 2023-06-30 13F ATEA PHARMACEUTICALS COM 04683R106 61,302 6,395 11.65 229 25.14 0.0020
2023-05-10 2023-03-31 13F ATEA PHARMACEUTICALS COM 04683R106 54,907 -1,705 -3.01 184 -32.72 0.0016
2023-02-14 2022-12-31 13F ATEA PHARMACEUTICALS COM 04683R106 56,612 56,612 272 0.0024
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.